CBG

Cannabigerol, abbreviated CBG, is one of more than a hundred cannabinoids produced by cannabis. It is the decarboxylated form of cannabigerolic acid (CBGA), which serves as the common precursor from which the plant biosynthesizes the more familiar cannabinoids such as THC and CBD; for this reason CBG is often described as the mother, or parent, cannabinoid ^[1][2]. Because most CBGA is converted into other cannabinoids as the plant matures, finished cannabis typically contains only a small percentage of CBG, though some cultivars are bred to produce more ^[1].

CBG is a non-intoxicating compound that has attracted growing scientific and commercial interest, but the research remains at an early stage. Laboratory and animal studies have explored possible anti-inflammatory, antibacterial, neuroprotective, and anticancer activities; for example, CBG reduced pro-inflammatory cytokine levels in preclinical models and showed activity against glioblastoma cells in the laboratory ^[1][3][4]. Reviews emphasize that, despite promising signals, there are as yet no firm conclusions about its therapeutic effectiveness or safety in humans ^[1][2]. Research has also examined its tolerability in topical and cosmetic use ^[5].

Pharmacologically, CBG behaves differently from THC and CBD; it is only a weak partial agonist at the classical cannabinoid receptors CB1 and CB2 and appears to act more strongly at other targets, including alpha-2 adrenergic and serotonin 5-HT1A receptors ^[1]. Its regulatory position mirrors that of other hemp cannabinoids; in the United States, CBG derived from hemp with very low THC is treated differently from CBG derived from marijuana, and it is not scheduled internationally as a psychotropic substance ^[1].

CBG is sold, much like CBD, as oils, tinctures, capsules, and topical products, sometimes marketed on its own and sometimes blended with other cannabinoids. Because it is present in low amounts naturally, producers may rely on selectively bred high-CBG cultivars or on biotechnological methods to obtain it ^[2][5].

Cannabigerol (CBG) appears generally well tolerated, though systematic human safety data remain limited. A double-blind placebo-controlled single-ascending-dose trial (25 to 200 mg oral) in healthy adults found a favorable tolerability profile with only two adverse events, both judged unrelated to the drug. In user surveys the most common complaints are mild and reversible within a day or two: dry mouth, sleepiness or sedation, increased appetite, dry eyes, and occasional GI upset, lightheadedness or lowered heart rate. The practical caution is drug interactions; CBG can affect cytochrome P450 enzymes and so may alter metabolism of co-administered medications. The honest limitation is that chronic dosing has not been studied, so long-term safety is uncharacterized, and its non-intoxicating reputation should not be read as fully validated.